US Patent

US9259425 — Compositions and methods for eye whitening

Method of Use · Assigned to Eye Therapies LLC · Expires 2030-07-14 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions and methods for whitening eyes using low concentrations of selective α-2 adrenergic receptor agonists, preferably including brimonidine.

USPTO Abstract

The invention provides compositions and methods for whitening of eyes. The provided compositions and methods utilize low concentrations of selective α-2 adrenergic receptor agonists. The compositions preferably include brimonidine.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2222 — Alphagan
U-2222 — Alphagan

Patent Metadata

Patent number
US9259425
Jurisdiction
US
Classification
Method of Use
Expires
2030-07-14
Drug substance claim
No
Drug product claim
No
Assignee
Eye Therapies LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.